Masimo Co. (NASDAQ:MASI) Holdings Boosted by RFG Advisory LLC

RFG Advisory LLC raised its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 73.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,780 shares of the medical equipment provider's stock after acquiring an additional 2,875 shares during the period. RFG Advisory LLC's holdings in Masimo were worth $1,130,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in MASI. FMR LLC lifted its holdings in shares of Masimo by 19.8% in the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock worth $1,338,509,000 after purchasing an additional 1,340,836 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of Masimo by 80.5% in the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock worth $405,807,000 after acquiring an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Masimo by 119.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock valued at $286,823,000 after purchasing an additional 943,001 shares during the last quarter. Alliancebernstein L.P. grew its position in Masimo by 1,276.9% in the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider's stock worth $156,604,000 after purchasing an additional 878,587 shares during the last quarter. Finally, Corient Private Wealth LLC increased its stake in shares of Masimo by 8,847.1% in the fourth quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider's stock valued at $57,472,000 after purchasing an additional 343,797 shares during the period. 85.96% of the stock is owned by institutional investors.

Masimo Stock Performance

Shares of MASI opened at $164.72 on Friday. The firm has a market cap of $8.93 billion, a price-to-earnings ratio of 113.60 and a beta of 1.19. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The company's fifty day moving average is $156.96 and its 200-day moving average is $167.24. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. The firm had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company's revenue was down 24.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.77 earnings per share. Equities analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Piper Sandler reiterated an "overweight" rating and set a $200.00 price objective (down from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Raymond James dropped their target price on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a report on Thursday, April 10th. BTIG Research set a $193.00 price target on shares of Masimo and gave the company a "buy" rating in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company decreased their price objective on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $191.60.

Insider Buying and Selling

In related news, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now directly owns 16,581 shares of the company's stock, valued at $2,754,601.53. This trade represents a 11.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Bilal Muhsin sold 10,000 shares of the company's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares of the company's stock, valued at $3,946,804.16. The trade was a 29.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,053 shares of company stock valued at $6,998,565. Insiders own 9.70% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.